Stocks-2 News

Nurix Therapeutics Presents Preclinical Data from Two Autoimmune and Inflammatory Disease Programs, NX-5948 and GS-6791, at ACR Convergence 2024

Data demonstrate potential superiority of a targeted protein degradation strategy compared to kinase inhibition for both BTK and IRAK4 targets in select inflammatory and autoimmune diseases Data demonstrate potential superiority of a targeted protein degradation strategy compared to kinase inhibition for both BTK and IRAK4 targets in select inflammatory and autoimmune diseases

The Schall Law Firm Urges Stockholder Participation In A Fraud Case Against Elanco Animal Health Incorporated

LOS ANGELES, CA / ACCESSWIRE / November 17, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Elanco Animal Health Incorporated ("Elanco" or "the Company") (NYSE: ELAN) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between November 7, 2023 and June 26, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before December 6, 2024.

Atlas Copco Is Perpetually Overvalued - A Q3'24 Wrap-Up

Atlas Copco is a high-quality, fundamentally sound company but is currently overvalued, trading at a premium of over 30x P/E. Despite a solid business model and high-value customers, the company's valuation remains too high for an attractive investment. I recommend a "Hold" rating, with an ideal entry point at 120 SEK/share, offering a realistic upside based on earnings growth.

ROSEN, A GLOBALLY RESPECTED INVESTOR RIGHTS FIRM, Encourages Lilium N.V. Investors to Secure Counsel Before Important Deadline in Securities Class Action – LILM, LILMF

NEW YORK, Nov. 17, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Lilium N.V. (NASDAQ: LILM) (OTC: LILMF) between June 11, 2024 and November 3, 2024, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than January 6, 2025.

Aviation Specialist Kratos Notches 4th Straight Profit. Is This Defense Stock Unstoppable Now?

Aviation Specialist Kratos Notches 4th Straight Profit. Is This Defense Stock Unstoppable Now?

Energy Stocks Have Soared This Year, but, These 3 Still Look Like Great Buys

Energy Stocks Have Soared This Year, but, These 3 Still Look Like Great Buys

Power Corporation of Canada: Undervalued With Strong Long-Term Growth Potential

I've maintained a 'buy' rating on Power Corporation of Canada due to its compelling valuation and 21% discount to NAV, offering significant value. The stock's 23.7% total return since March 2024, driven by a 20.1% share price rise and $0.56 quarterly dividend, outperformed the S&P 500 by nearly 12%. Despite a Q3'24 EPS miss and a 5% share price drop, the company's strong portfolio and shareholder returns through dividends and buybacks remain attractive.

Class Action Filed Against Edwards Lifesciences Corporation (EW) Seeking Recovery for Investors - Contact Levi & Korsinsky

NEW YORK, NY / ACCESSWIRE / November 17, 2024 / If you suffered a loss on your Edwards Lifesciences Corporation (NYSE:EW) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/edwards-lifesciences-lawsuit-submission-form?prid=112265&wire=1 or contact Joseph E. Levi, Esq.

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of January 13, 2025 in PACS Group, Inc. Lawsuit - PACS

NEW YORK, NY / ACCESSWIRE / November 17, 2024 / If you suffered a loss on your PACS Group, Inc. (NYSE:PACS) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/pacs-group-inc-lawsuit-submission-form?prid=112263&wire=1 or contact Joseph E. Levi, Esq.

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of November 25, 2024 in Metagenomi Lawsuit - MGX

NEW YORK, NY / ACCESSWIRE / November 17, 2024 / If you suffered a loss on your Metagenomi, Inc. (NASDAQ:MGX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/metagenomi-lawsuit-submission-form?prid=112262&wire=1 or contact Joseph E. Levi, Esq.

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Zeta Global Holdings Corp. (ZETA) And Encourages Investors to Reach Out

NEW YORK CITY, NY / ACCESSWIRE / November 17, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Zeta Global Holdings Corp. ("Zeta" or "the Company") (NYSE:ZETA). Investors who purchased Zeta securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ZETA.

Quanterix Corporation (QTRX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

NEW YORK CITY, NY / ACCESSWIRE / November 17, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Quanterix Corporation ("Quanterix" or "the Company") (NASDAQ:QTRX). Investors who purchased Quanterix securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/QTRX.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of JFrog Ltd. - FROG

NEW YORK, NY / ACCESSWIRE / November 17, 2024 / Pomerantz LLP is investigating claims on behalf of investors of JFrog Ltd. ("JFrog" or the "Company") (NASDAQ:FROG).

Neurogene Inc. (NGNE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

NEW YORK CITY, NY / ACCESSWIRE / November 17, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Neurogene Inc. ("Neurogene" or "the Company") (NASDAQ:NGNE). Investors who purchased Neurogene securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/NGNE.

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Celanese Corporation (CE) and Encourages Investors to Learn More About the Investigation

NEW YORK CITY, NY / ACCESSWIRE / November 17, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Celanese Corporation ("Celanese" or "the Company") (NYSE:CE). Investors who purchased Celanese securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/CE.

Myriad Genetics, Inc. (MYGN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

NEW YORK CITY, NY / ACCESSWIRE / November 17, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Myriad Genetics, Inc. ("Myriad" or "the Company") (NASDAQ:MYGN). Investors who purchased Myriad securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/MYGN.

Bronstein, Gewirtz & Grossman, LLC Is Investigating Huntington Ingalls Industries, Inc. (HII) And Encourages Shareholders to Connect

NEW YORK CITY, NY / ACCESSWIRE / November 17, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Huntington Ingalls Industries, Inc. ("Huntington Ingalls" or "the Company") (NYSE:HII). Investors who purchased Huntington Ingalls securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/HII.

The Bancorp, Inc. (TBBK) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

NEW YORK CITY, NY / ACCESSWIRE / November 17, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of The Bancorp, Inc. ("Bancorp" or "the Company") (NASDAQ:TBBK). Investors who purchased Bancorp securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/TBBK.

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against DZS, Inc. (DZSI) And Encourages Stockholders to Reach Out

NEW YORK, NY / ACCESSWIRE / November 17, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of DZS, Inc. ("DZS" or "the Company") (NASDAQ:DZSI). Investors who purchased DZS securities prior to March 10, 2023, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/DZSI.

Delta Air Lines: Just The Start

Delta Air Lines is finally trading above pre-Covid levels, overcoming the July IT outage. Cruise lines and other industrial transport stocks still trade at higher valuation multiples, suggesting the airline rally is only getting started. DAL stock trades below 9x '25 EPS targets, still offering a cheap value.